Pretreatment with interferon-α2a modulates perioperative immunodysfunction in patients with renal cell carcinoma

Onkologie

Volumn 31, Issue 1-2, 2008, Pages 28-34

  Klatte, T ^a   Ittenson, A ^a   Rohl F W ^a   Ecke, M ^b   Allhoff, E P ^a   Bohm M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Klinik für Gynäkologie und Geburtshilfe   (Germany)

Author keywords

Immunomodulation; Interferon; Regulatory T cells; Sorafenib; Sunitinib

Indexed keywords

ALPHA INTERFERON; CD19 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; FLUOROURACIL; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ALPHA2A INTERFERON; VASCULOTROPIN; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; VASCULOTROPIN A;

ADULT; AGED; AGRANULOCYTOSIS; ANEMIA; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; FLUSHING; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HUMORAL IMMUNITY; HYPOCALCEMIA; IMMUNOMODULATION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; SIDE EFFECT; THROMBOCYTOPENIA; VENOUS BLOOD; VOMITING; ADJUVANT THERAPY; ANTIBODY PRODUCTION; BLOOD; CANCER STAGING; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNE DEFICIENCY; IMMUNOLOGY; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATION; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY FORMATION; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERFERON ALFA-2A; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39149105595     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112214     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS: Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int 2007;99:821-824.
3. Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, Abbou CC, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS: Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 2007;52:155-162.
4. Russo P: For small renal tumors, kidney sparing surgery provides local tumor control and prevents chronic kidney disease. Onkologie 2007;30:92-93.
5. Adamakis I, Koutalellis G, Mitropoulos D, Vourekas S, Constantinides C, Zervas A: Enucleoresection for the elective treatment of small renal cell carcinoma: can it be the treatment of choice? Onkologie 2007;30:97-102.
6. O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, Grainger R, McDermott TE, Mullins G, O'Brien A, Twomey A, Thornhill J: Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 2004;45:613-618.
7. Mulder SF, van Spronsen DJ, De Mulder PH: Do the results of the new trials change the standard treatment of metastatic renal cell cancer? Onkologie 2007;30:260-264.
8. Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int 2005;96:483-488.
9. McKiernan JM, Buttyan R, Bander NH, De la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS: The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 1999;86:492-497.
10. Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T: Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res 2000;6:3817-3822.
11. Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-746.
12. Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, McKiernan JM: Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 2006;67:942-945.
13. Böhm M, Ittenson A, Philipp C, Röhl FW, Ansorge S, Allhoff EP: Complex perioperative immuno-dysfunction in patients with renal cell carcinoma. J Urol 2001;166:831-836.
14. Böhm M, Klatte T, Allhoff EP: Perioperative immune modulation in renal cell carcinoma - review of the current situation. Aktuelle Urol 2003;34:319-327.
15. Flörcken A, Denecke T, Kretzschmar A, Gollasch H, Reich G, Westermann J: Long-lasting remission of pulmonary metastases of renal cell cancer under IFN-beta therapy in a patient with multiple sclerosis. Onkologie 2006;29:382-384.
16. Aass N, de Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ: Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 2005;23:4172-4178.
17. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M: Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:1188-1194.
18. Böhm M, Ittenson A, Schierbaum KF, Röhl FW, Ansorge S, Allhoff EP: Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma. Eur Urol 2002;41:458-467.
19. Klatte T, Ittenson A, Röhl FW, Ecke M, Allhoff EP, Böhm M: Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial. Br J Cancer 2006;95:1167-1173.
20. Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T: Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative alpha-interferon in patients with renal cell carcinoma. J Urol 1994;152:852-856.
21. Sejima T, Miyagawa I: The evaluation of Fas/Fas ligand system in renal cell carcinoma-the effect of preoperative interferon-alpha therapy. Nippon Hinyokika Gakkai Zasshi 1999;90:826-832.
22. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H: Guidelines on renal cell cancer. Eur Urol 2001;40:252-255.
23. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM: Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-134.
24. Donskov F, Bennedsgaard KM, von der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M: Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002;87:194-201.
25. Naveau S, Emilie D, Borotto E, Portier A, Lazizi Y, Giraud V, Grangeot-Keros L, Capron F, Galanaud P, Chaput JC: Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment. J Hepatol 1997;27:272-275.
26. Aman MJ, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky WE, Tilg H, Huber C, Peschel C: Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996;87:4731-4736.
27. Van Spronsen DJ, De Mulder PH: Targeted approaches for treating advanced clear cell renal carcinoma. Onkologie 2006;29:394-402.
28. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-3295.
29. Ryan CW, Goldman BH, Lara PN, Jr., Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 2007;25:3296-3301.
30. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
31. Beyer M, Schultze JL: Regulatory T cells in cancer. Blood 2006;108:804-811.
32. Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P, Shaheen P, Garcia J, Dreicer R, Bukowski R: T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. J Clin Oncol (Annual Meeting Proceedings) 2006;24:2526.
33. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-3633.
34. Miyara M, Sakaguchi S: Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007;13:108-116.
35. Ramsdell F, Ziegler SF: Transcription factors in autoimmunity. Curr Opin Immunol 2003;15:718-724.
36. Houvenaeghel G, Bladou F, Blache JL, Olive D, Monges G, Jacquemier J, Chaudet H, Delpero JR, Guerinel G: Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers. Int Surg 1997;82:165-169.
37. Cockerell OC, Oliver RT, Nethersall A: Nephrectomy combined with perioperative alpha-interferon in the treatment of advanced local and minimally metastatic renal cell cancer. Urol Int 1991;46:46-49.
38. Belldegrun A, Pierce W, Kaboo R, Tso CL, Shau H, Turcillo P, Moldawer N, Golub S, deKernion J, Figlin R: Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol 1993;150:1384-1390.
39. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214-1222.
40. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425-431.
41. Skolarikos A, Alivizatos G, Laguna P, de la Rosette J: A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 2007;51:1490-1501.